Translational development and first-in-human compassionate infusion of NK-92 cells expressing a CD5-based chimeric antigen receptor (SRCD5CAR-NK-92) in a patient with multidrug-resistant fusariosis
María Velasco‐de Andrés·Francisco Lozano·Jiří Eitler·Lydia Krutz·Mariana Chumbita·Marta Español‐Rego·Cristina Català·Laura Carrillo‐Serradell·Violeta Planells-Romeo·Lucía Aragón-Serrano·Andrea Vergara·Amanda Isabel Pérez‐Valencia·Patricia Monzó·Antonio Gallardo‐Pizarro·María Teresa Cibeira·A Vlagea·José Luis Caro·Eduard Palou·María Suárez‐Lledó·Àlex Soriano·Gonzalo Calvo·Álvaro Urbano-Ispizua·Torsten Tonn·Carolina García‐Vidal·Pedro Puerta‐Alcalde
Introduction Invasive fungal infections (IFI) remain a major therapeutic challenge due to limited antifungal options, emergence of multidrug-resistant (MDR) strains and high mortality rates. This has turned up the development of immune-based therapies to restore and/or enhance anti-fungal immune responses into a clinical priority. This is in line with the recent demonstration that antifungal activity of primary (cord blood-derived) NK cells can be potentiated by endowing them with a CD5-based se